The same pharmacogenomics that sits on our condition pages, read from the other end. People rarely arrive asking about SLCO1B1 — they arrive having been prescribed a statin. Each page below collects what published guidelines say about one drug, names the genes involved, and links to the variants your own file would contain.
Supplements — kept apart, with the evidence stated on each →
None of this is dosing guidance. Where a clinical guideline exists it is written for prescribers, and the pages say so. Nothing here is a reason to start, stop or change a medication.
Your cells have tiny doors that let salt and water out. The CFTR gene is the blueprint for them, and cystic fibrosis is what happens when the blueprint has a typo. Trikafta puts the door back in place and opens it, but whether it works depends on which typo you carry.
CFTR
See what the research says → CFTR modulatorNot a drug for cystic fibrosis — a drug for particular CFTR variants. Two people with the same diagnosis get opposite answers depending on which change they carry, which is the whole argument of this site in one prescription.
CFTR
See what the research says → CFTR modulatorThe same idea as Trikafta, rebuilt: two medicines set the CFTR door in place and one opens it, now in a single dose a day. Who can take it still depends on which CFTR typo you carry.
CFTR
See what the research says →The same pharmacogenomics already published on our condition pages, read from the drug side instead: what published guidelines say about one medicine, which genes are involved, and the variants your own file would contain.
No. Where a clinical guideline exists it is written for prescribers, and nothing here is a reason to start, stop or change a medication — that belongs with the clinician or pharmacist managing treatment.
Because almost nothing sold as a supplement has a prescribing guideline behind it the way a drug does, and listing the two together would lend the second the authority of the first.
By gene symbol as a whole word, gathered from the pgx_notes already published on the condition pages that discuss each drug — not a second, separate copy of that information.